180. Weisberg E et al (2005) Characterization of AMN107, a selective inhibitor of native and
mutant Bcr-Abl. Cancer Cell 7:129
181. Gumireddy K et al (2005) A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib
resistance. Proc Natl Acad Sci U S A 102:1992
182. Gumireddy K et al (2005) ON01910, a non-ATP-competitive small molecule inhibitor of Plk1,
is a potent anticancer agent. Cancer Cell 7:275
183. Copland M et al (2008) BMS-214662 potently induces apoptosis of chronic myeloid leukemia
stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 111:2843
184. Orphanos GS, Ioannidis GN, Ardavanis AG (2009) Cardiotoxicity induced by tyrosine kinase
inhibitors. Acta Oncol 48:964
185. Shah DR, Shah RR, Morganroth J (2013) Tyrosine kinase inhibitors: their on-target toxicities
as potential indicators of efficacy. Drug Saf 36:413
186. Mayor S (2006) Targeting cardiovascular complications. Lancet Oncol 7:282
187. Moslehi JJ, Deininger M (2015) Tyrosine kinase inhibitor–associated cardiovascular toxicity
in chronic myeloid leukemia. J Clin Oncol 33:4210
188. Bernards R, Brummelkamp TR, Beijersbergen RL (2006) shRNA libraries and their use in
cancer genetics. Nat Methods 3:701
Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical. . .
153